Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method

Journal of Clinical Microbiology

Volumn 36, Issue 10, 1998, Pages 3020-3027

  Gravitt, P E ^a,c   Peyton, C L ^b   Apple, R J ^a   Wheeler, C M ^b  

^a ROCHE MOLECULAR SYSTEMS   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; DNA DETERMINATION; DOT HYBRIDIZATION; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN CELL; OLIGONUCLEOTIDE PROBE; PAPANICOLAOU TEST; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS DETECTION;

BOVINAE; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0031683626     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.10.3020-3027.1998     Document Type: Article

References (24)

1. Bauer, H. M., C. E. Greer, and M. M. Manos. 1992. Determination of genital human papillomavirus infection using consensus PCR, p. 132-152. In C. S. Herrington and J. O. D. McGee (ed.), Diagnostic molecular pathology: a practical approach. Oxford University Press, Oxford, United Kingdom.
2. Bosch, F. X., N. Munoz, S. de Sanjose, C. Navarro, P. Moreo, N. Ascunce, L. C. Gonzalez, L. Tafur, M. Gili, I. Larranaga, et al. 1993. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol. Biomarkers Prev. 2:415-422.
3. Bosch, F. X., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, K. V. Shah, and the IBSCC Study Group. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
4. Bugawan, T. L., R. Apple, and H. Erlich. 1994. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens 44:137-147.
5. Cox, J. T., A. T. Lorincz, M. H. Schiffman, M. E. Sherman, A. Cullen, and R. J. Kurman. 1995. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 172: 946.
6. Cuzick, J., A. Szarewski, G. Terry, L. Ho, A. Hanby, P. Maddox, M. Anderson, G. Kocjan, S. T. Steele, and J. Guillebaud. 1995. Human papillomavirus testing in primary cervical screening. Lancet 345:1533.
7. Franco, E. L. 1991. The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology 2:98-106.
8. Franco, E. L. 1992. Measurement errors in epidemiological studies of human papillomavirus and cervical cancer, p. 181-197. In N. Munoz, F. X. Bosch, K. J. Shah, and A. Meheus (ed.), The epidemiology of human papillomavirus and cervical cancer. Oxford University Press, Oxford, United Kingdom.
9. Franco, E. L. 1997. Statistical issues in studies of human papillomavirus infection and cervical cancer, p. 39-50. In E. Franco and J. Monsonego (ed.), New developments in cervical cancer screening and prevention. Blackwell Science Ltd., Oxford, United Kingdom.
10. Hildesheim, A., M. H. Schiffman, P. E. Gravitt, A. G. Glass, C. E. Greer, T. Zhang, D. R. Scott, B. B. Rush, P. Lawler, M. Sherman, R. J. Kuman, and M. M. Manos. 1994. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169:235-240.
11. Ho, G. Y. F., R. D. Burk, S. Klein, A. S. Kadish, C. J. Chang, P. Palan, J. Bassu, R. Tachezy, R. Lewis, and S. Romney. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1365-1371.
12. International Agency for Research on Cancer. 1995. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol. 64. Human papillomaviruses. International Agency for Research on Cancer, Lyon, France.
13. Jacobs, M. V., P. J. F. Snijders, A. J. C. van den Bruie, T. J. M. Helmerhorst, C. J. L. M. Meijer, and J. M. M. Walboomers. 1997 A general primer GP5+/6-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35:791-795.
14. Koutsky, L. A., K. K. Holmes, C. W. Critchlow, C. E. Stevens, J. Paavonen, A. M. Beckmann, T. A. DeRouen, D. A. Galloway, D. Vernon, and N. B. Kiviat. 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 327: 272-278.
15. Liaw, K.-L., A. W. Hsing, C. J. Chen, M. H. Schiffman, T. Y. Zhang, C. Y. Hsieh, C. E. Greer, S. L. You, T. W. Huang, T. C. Wu, et al. 1995. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int. J. Cancer 62:565-571.
16. Manos, M. M., J. Waldman, T. Y. Zhang, C. E. Greer, G. Eichinger, M. H. Schiffman, and C. M. Wheeler. 1994. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J. Infect. Dis. 170: 1096-1099.
17. Meijer, C. J. L. M., L. Rozendaal, J. C. van der Linden, et al. 1997. Human papillomavirus testing for primary cervical screening, p. 338-347. In E. Franco and J. Monsonego (ed.), New developments in cervical cancer screening and prevention. Blackwell Science Ltd., Oxford, United Kingdom.
18. Mould, T. A., and A. Singer. 1997. Human papillomavirus testing for diagnostic triage of minor-grade cytological abnormalities: the European perspective, p. 354-359. In E. Franco and J. Monsonego (ed.), New developments in cervical cancer screening and prevention. Blackwell Science Ltd., Oxford, United Kingdom.
19. Qu, W., G. Jiang, Y. Cruz, C. J. Chang, G. Y. F. Ho, R. S. Klein, and R. D. Burk. 1997. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J. Clin. Microbiol. 35:1304-1310.
20. Remmink, A. J., J. M. M. Walboomers, T. J. M. Helmerhorst, F. J. Voorhorst, L. Rozendaal, E. K. J. Risse, C. J. L. M. Meijer, and P. Kenemans. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61:306-311.
21. Saiki, R. K., P. S. Walsh, C. H. Levenson, and H. A. Erlich. 1989. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc. Natl. Acad. Sci. USA 86:6230-6234.
22. Schiffman, M. H. 1995. New epidemiology of human papillomavirus infection and cervical neoplasia. J. Natl. Cancer Inst. 87:1345-1347.
23. Schiffman, M., H. Bauer, R. Hoover, A. G. Glass, D. M. Cadell, B. B. Rush, D. R. Scott, M. E. Sherman, R. J. Kurman, S. Wacholder, C. K. Stanton, and M. M. Manos. 1993. Epidemiologic evidence showing that HPV infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 85:958-964.
24. Sherman, M. E., M. H. Schiffman, A. T. Lorincz, M. M. Manos, D. R. Scott, R. J. Kurman, N. B. Kiviat, M. Stoler, A. G. Glass, and B. B. Rush. 1994. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am. J. Clin. Pathol. 2:182-187.